Menopause & Hormone Therapy Watch

Track menopause care for US women. Report only confirmed, source-backed items from the last 7 days: FDA approvals, label changes and boxed warning decisions for hormone therapy including estradiol, progesterone and vaginal estrogen products and non-hormonal drugs including fezolinetant and elinzanetant; guideline updates from The Menopause Society, ACOG, Endocrine Society and USPSTF; generic launches and price changes; Medicare Part D and major insurer formulary and prior authorization changes; FTC, FDA or state actions involving telehealth menopause clinics and compounded hormone products; workplace menopause policy adoptions at large employers; and peer-reviewed study results in JAMA, NEJM, Lancet or Menopause with a clear clinical implication. Prefer FDA, society, insurer, journal and company sources; ignore supplement and influencer claims. Put the drug or guideline first in the title. Use high severity for a boxed warning change, a guideline reversal, or a formulary change affecting a top-10 menopause product. Return no more than 6 findings. Push each as a finding with a title, a two-sentence summary, sections for what changed, who it applies to, what to discuss with a clinician, and the source link. Note that findings are informational and not medical advice. If nothing qualifies, push nothing and submit the run receipt.